

**Asian Centre for Liver Diseases and Transplantation Limited**

ABN 42 091 559 125

3 November 2009

The Companies Announcement Office  
ASX Limited

Dear Sir,

**Additional Information**

**Corrigendum to Appendix 4E**

The Board of Directors would like to refer you to Page 2 of the preliminary final report (Appendix 4E), under the head of “Brief explanation of the Revenue and Net Profit”.

Due to inadvertent typo errors, the previously announced statements should be read as:

“The decline in Revenue was **NOT** primarily due to global financial crisis with less patients seeking for treatments and **the Directors have provided the detailed explanation notes and relevant financial ratios (proforma) in Appendix 1 and 2 respectively**”

instead of

“The decline in Revenue was primarily due to global financial crisis with less patients seeking for treatments”. This statement was incomplete.

**Additional Financial Information**

We have also provided the following additional financial information for your review.

1. Please refer to attached **Appendix 1 for financial review** providing explanatory notes in relation to financial performance, retained earnings, reconciliation and brief notes on cash flows position.
2. Please refer to **Appendix 2 for proforma key financial ratios** highlighting the Investment ratios, Financial Performance ratios and Financial Position Ratios of the Company.

For personal use only

## Appendix 1

You would have noted that the following additional information is a voluntary disclosure by the Company. Despite being a small company, we appreciate continual disclosure of relevant corporate information with a view to enhance shareholders' communication.

### Background

On 14 August 2009, the Company (formerly known as Costarella Design Limited), completed the acquisition of Asian Centre For Liver Diseases & Transplantation Inc ("ACLDT Inc"), which owns 100% of Asian Centre For Liver Diseases & Transplantation Pte. Ltd ("ACLDT Singapore") ("the Acquisition"). Upon successful completion of the acquisition, the Company now owns two legal subsidiaries, namely ACLDT Inc and ACLDT Singapore. ACLDT Inc is an investment holding company and ACLDT Singapore is the Company's key operations.

### Basis of presentation of Financial Information

The financial year end of the Company has been 30 June whereas the financial year end for ACLDT Singapore has been 31 August. The Company intends to change its financial year end to 31 August and the first full-year financial results of the Company following the proposed change of the financial year end is expected to be released only for the year ending 31 August 2010. As such, the financial information set out in Appendix 4E relates to *Proforma Financial Statement of the Company for the financial year ended 31 August 2008 and 31 August 2009*, have been presented for your information on the assumption that the Acquisition had been completed throughout the period under review.

Please also note that the financial information set out in Appendix 4E is not a consolidated financial statement of the Company. It relates to the financial information of ACLDT Singapore, the key subsidiary of the Company (which is also the key operation of the Company). The Company will only announce its first set of consolidated results for the half yearly report ending 28 February 2010 before 30 April 2010.

The financial information is expressed in Singapore Dollars ("S\$")

### Review of Financial Performance

#### Revenue

Revenue fell by 15.9% or S\$3.3 million to S\$17.7 million for the year ended 31 August 2009 (FY2009). The fall in revenue was not primarily due to the global financial crisis, which has been widely discussed as the root cause for the disappointing sets of results

across most of the industry – we operate in a market niche. The revenue fall during the financial year was much relating to patients’ care and strategic reasons resulting in less-than optimum capacity utilization during the year under review:

- Revenue growth was much limited by the number of surgeons we have – our chairman mentioned in his previous letter to shareholders that the current revenue was achieved based on the fact that our operations were only supported by 3 consultants. During the year under review, we received more urgent non-transplantation cases and we treated these patients in accordance with our list of priority despite the fact that the income derived from non-transplantation case is generally lower compared to a liver transplantation. Had our operations not been restricted by the number of surgeons, we would have been able to perform more liver transplantations in addition to those urgent cases we received. Whilst we understand that the decision has been carried out at the expense of our revenue growth, our patients-care policies were not compromised.
- Part of our intensified marketing effort is to expand and diversify our bases of patients with the objective of receiving cases from emerging markets. The busy overseas marketing schedules had resulted in us re-scheduling some of our non-urgent procedures and have thus progressively pushed these appointments towards later dates – some of these appointments fell into first-quarter of next financial year. Our key consultant surgeon, who is also our Chairman, has been extensively involved in the corporate marketing programs (prior to the appointment of our new COO). The marketing efforts, however, have resulted in us being able to receive new cases from Indonesia, Vietnam, Russia and Mongolia. It was a good move.

As previously mentioned in our letter to shareholders, we have proactively addressed the above-mentioned issues. We have initiated discussions with experienced surgeons, one of whom will be joining us next April, another is expected to be confirmed in the next 3 – 6 months. In addition, a corporate COO has been recruited to streamline the marketing and operations process with the objectives of handling more patients’ referral cases. We will provide necessary update to shareholders as and when required.

Given the above-mentioned, the fall was considered moderate (there were only 8 transplantation cases lesser than that of FY2008) and it was much within our expectation as a result of our bold strategic move.

## **Net Profit after Tax (“Net Profit”)**

We provide herewith the Gross Profit analysis. The related figures were extracted from Page 6 of our Income Statement.

	FY2009	FY2008
	S\$' 000	S\$' 000
<b>Revenue</b>	<b>17,704</b>	<b>21,038</b>
Changes in inventories	64	(357)
Inventories	(1,521)	(1,811)
Purchased services	(9,186)	(11,776)
<b>Cost of Sales</b>	<b>(10,643)</b>	<b>(13,944)</b>
<b>Gross Profit</b>	<b>7,061</b>	<b>7,094</b>
<b>Gross Profit margin</b>	<b>39.9%</b>	<b>33.7%</b>

Gross Profit remained relatively stable at approximately S\$7.1 million despite a year-on-year 15.9% fall in Revenue which means an improvement in gross margin during the year under review. Gross margin improved sharply by 6.2 percentage points to about 40% for FY2009 due mainly to effective marketing program that we were able to receive increased number of patients from more diversified bases on which we could charge premium for certain complicated cases. Despite higher gross profit margin, Net Profit, on the face of Income Statement, fell by S\$0.5 million to S\$1.9 million as a result of increased operating expenses. Specifically that (it was generally mentioned in our previous letter to shareholders):-

- staff cost rose by S\$0.5 million due mainly to increased headcount under our expansion plans and inflationary salary adjustments;
- additional rental of \$0.4 million due mainly to retrospective adjustments for operating leases and taking up of larger operating space;
- there were other non-recurring corporate expenses – such as legal and professional fees – incurred in connection with the completion of the acquisition exercise.

Net Profit margin for FY2009, however, remained relatively constant at about 10.9% compared to 11.5% for FY2008.

## Financial Position

We provide herewith the Retained Earnings reconciliation:-

	Note	As at 31 August 2009 S\$' 000	As at 31 August 2008 S\$' 000
Retained Earnings before pre-acquisition dividends		5,000	3,065
Pre-acquisition dividends *	Note 13	(3,206)	-
Retained Earnings after pre-acquisition dividends (per Balance Sheet)		<u>1,794</u>	<u>3,065</u>

\* *pre-acquisition dividends means dividend declared and paid prior to completion of the Acquisition.*

The above table shows an increase of S\$1.9 million in Retained Earnings before pre-acquisition dividends of S\$3.2 million as a result of current year earnings. Retained Earnings fell by S\$1.3 million to S\$1.8 million following the payments of pre-acquisition dividends.

## Cash Flows

The Company net cash position increased sharply by S\$1.4 million to S\$3.9 million due mainly to current year earnings (cash profit in equivalent), less additional working capital investment during the year. The Company's gearing ratio remained zero.

## Appendix 2

### Proforma Key Financial Ratios

#### Investment Ratios

	<b>FY2009</b>
Earnings per ordinary share (S cents)	<b>1.00 cent</b>
Net Asset Value per ordinary share (S cents) – before pre-acquisition dividends	<b>2.65 cents</b>
Net Asset Value per ordinary share (S cents) – after pre-acquisition dividends	<b>0.95 cents</b>
Cash per ordinary share (S cents)	<b>2.03 cents</b>
Return on Equity	<b>107.9%</b>
Return on Assets	<b>24.9%</b>

For personal use only

**Financial Performance Ratios**

Gross margin (%)

**39.9%**

Net Margin (%)

**10.9%**

**Financial Position Ratios**

Current ratio (times)

**1.28 times**

Quick Ratio (times)

**1.23 times**

Average Inventories turnover (days)

**12.45 days**

Average Trade receivables turnover (days)

**66.51 days**

Average Trade payables turnover (days)

**143.73 days**

Notes

**Proforma number of shares used in computing the related ratios**

**188,454,000**

On behalf of the Board



\_\_\_\_\_  
K.Tang

Non-executive Director